Clinical trials: Best Disease
Urothelial Cancer
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic…
- Trial name
- NCT02603432
- Testing
- Avelumab, Best Supportive Care, Following the planned interim analysis for this study: Avelumab
- Where
- 382 sites in United States, Argentina and 27 more
- Volunteers
- 700 people
- Sponsor
- Pfizer
Asthma
DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults
The purpose of this study is to determine whether Symbicort dosed according to the Symbicort Maintenance and Reliever Therapy (SMART) concept is superior to standard asthma treatment according to the local German treatment…
- Trial name
- NCT00252863
- Testing
- Symbicort, used twice daily (b.i.d) and as needed (prn), Budesonide Turbuhaler 200 µg, Fluticasone Discus 250 µg
- Where
- 169 sites in Germany
- Volunteers
- 1,600 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
A Study Comparing of Two Different Chemotherapy Regimens, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This is a multicenter, open-label, randomized, two-arm Phase 2 study comparing pemetrexed plus best supportive care with best supportive care alone as maintenance therapy following first-line treatment with a pemetrexed-cisplatin…
- Trial name
- NCT00606021
- Testing
- pemetrexed, Best Supportive Care
- Where
- 5 sites in Egypt, Lebanon and 1 more
- Volunteers
- 106 people
- Sponsor
- Eli Lilly and Company
Myelodysplastic Syndromes
An Extension to Study AZA PH GL 2003 CL 001 Allowing for Continuation of Azacitidine Treatment in Patients With Myelodysplastic Syndromes (MDS)
At the conclusion of study AZA PH GL 2003 CL 001 (NCT00071799), eligible participants could be enrolled in an optional extension phase in order to continue treatment with azacitidine until it became commercially available; the…
- Trial name
- NCT01186939
- Testing
- Azacitidine
- Where
- 22 sites in Australia, Bulgaria and 9 more
- Volunteers
- 40 people
- Sponsor
- Celgene
Age Related Macular Degeneration (AMD)
A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)
This is a prospective pilot study to evaluate the usability and applicability of a self monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age Related Macular…
- Trial name
- NCT01542866
- Testing
- Health Management Tool (HMT)
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Ophthalmopathy
Assessing Agreement Between Acuvera Capture and Paper-Based Methods for BCVA Data Recording in Ophthalmic Trials
Study Purpose: To evaluate the level of agreement between the Acuvera Capture application and traditional paper-based methods for recording Best Corrected Visual Acuity (BCVA) in ophthalmic clinical trials.
- Trial name
- VALiCAPTURE (NCT07613580)
- Where
- 2 sites in Portugal
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- OptymEdge, LLC
Glioblastoma Multiforme
Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme
TransMID treatment or best standard of care for patients with advanced glioblastoma multiforme Glioblastoma multiforme (GBM) is a type of brain tumour. GBM tumours are usually treated with surgery and radiotherapy.
- Trial name
- NCT00083447
- Testing
- TransMID™
- Where
- 25 sites in United States, Australia
- Volunteers
- 323 people
- Sponsor
- Xenova Biomedix
HIV Infections
Safety Study of Once a Day ART and Opiate Substitute.
This study looks at HIV-infected subjects who are on methadone treatment and medicines for HIV.
- Trial name
- 3OD (NCT00324688)
- Testing
- Viread
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
COVID-19
Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge
The study is a prospective, pilot study aimed to test the safety of Tumor Treating Fields (TTFields) concomitant with best standard of care, for the treatment of hospitalized COVID-19 patients and continued treatment after…
- Trial name
- NCT04953234
- Testing
- NovoTTF-100L
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- NovoCure GmbH
Non-exudative (Dry) Age-related Macular Degeneration (AMD)
HELP Therapy for Dry AMD
This is an open-label, single center clinical investigation to evaluate the efficacy and safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a treatment for non-exudative (dry) Age-related…
- Trial name
- HELPuc (NCT01840683)
- Testing
- H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- B.Braun Avitum AG
Gastrointestinal Stromal Tumors
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors…
- Trial name
- GRID (NCT01271712)
- Testing
- Regorafenib (Stivarga, BAY73-4506), Best supportive care
- Where
- 57 sites in United States, Austria and 15 more
- Volunteers
- 199 people
- Sponsor
- Bayer
Polycythemia Vera
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
This pivotal phase III trial (CINC424B2301) is designed to compare the efficacy and safety of ruxolitinib (INC424) to Best Available Therapy (BAT) in participants with polycythemia vera (PV) who are resistant to or intolerant of…
- Trial name
- NCT01243944
- Testing
- ruxolitinib tablets, Best Available Therapy (BAT)
- Where
- 102 sites in United States, Argentina and 16 more
- Volunteers
- 222 people
- Sponsor
- Incyte Corporation
Stable Coronary Disease, Unstable Coronary Disease
Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen
To evaluate the safety and efficacy of the Janus OPTIMA Tacrolimus-Eluting Stent (Optima TES, CID) for the treatment of de novo coronary lesions when associated with short-term (two months) dual antiplatelet (aspirin +…
- Conditions
- Stable Coronary Disease, Unstable Coronary Disease, Documented Silent Ischemia
- Trial name
- BEST (NCT01122719)
- Testing
- Drug Eluting Stent
- Where
- 2 sites in Brazil, Italy
- Volunteers
- 16 people
- Sponsor
- CID - Carbostent & Implantable Devices
RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
This is an external control, observational, retrospective study designed to compare clinical outcomes for pralsetinib compared with best available therapy for patients with RET-fusion positive advanced NSCLC.
- Conditions
- RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms
- Trial name
- NCT04697446
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 279 people
- Sponsor
- Blueprint Medicines Corporation
Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC)
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
This study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over…
- Trial name
- Beacon-BTC (NCT07265674)
- Testing
- Nanvuranlat, Physician's Best Choice
- Where
- 18 sites in United States
- Volunteers
- 480 people
- Sponsor
- J-Pharma Co., Ltd.
Visual Acuity, Geographic Atrophy
A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy
The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.
- Conditions
- Visual Acuity, Geographic Atrophy, Macular Degeneration
- Trial name
- PRELUDE (NCT02659098)
- Testing
- CNTO 2476 3.0 x 10^5 cells, Subretinal Delivery System
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Researchers are looking for a better way to treat people who have advanced solid tumors. Advanced solid tumors are types of cancer that may have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that…
- Trial name
- NCT05614102
- Testing
- BAY2965501, Pembrolizumab, Platinum-based Chemotherapy
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 284 people
- Sponsor
- Bayer
Malignant Pleural Mesothelioma
NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
- Trial name
- NCT01098266
- Testing
- NGR-hTNF plus Best Investigator's Choice (BIC)
- Where
- 49 sites in United States, Belgium and 10 more
- Volunteers
- 400 people
- Sponsor
- AGC Biologics S.p.A.
Rheumatoid Arthritis
Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)
This is a 12 month prospective, multicenter, post-marketing, observational study to compare the effectiveness of a treat-to-target (T2T) disease management strategy vs.
- Trial name
- ABC (NCT03274141)
- Testing
- Non-Interventional
- Where
- Canada
- Volunteers
- 281 people
- Sponsor
- Bristol-Myers Squibb
Pancreatic Cancer
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer
The primary objectives of the study is to evaluate the effectiveness and safety of glufosfamide in subjects with pancreatic cancer who have been previously treated with gemcitabine as measured by overall survival compared with…
- Trial name
- NCT00099294
- Testing
- Glufosfamide
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 300 people
- Sponsor
- Threshold Pharmaceuticals